
Opinion|Videos|June 4, 2024
Academic and Community Practice Collaboration in mBC Treatment
Frank Scimeca, PharmD, MBA, BCOP, discusses the crucial collaborative effort between academic and community practices in managing and monitoring patients receiving CDK4/6 inhibitors, emphasizing the importance of communication and coordination to ensure optimal patient care.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
2
CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program
3
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
4
Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review
5





















